Sanofi, GSK, racing to catch up, begin their first human study of coronavirus vaccine

Sanofi, GSK, racing to catch up, begin their first human study of coronavirus vaccine

Source: 
BioPharma Dive
snippet: 

Though Sanofi and GSK have been slower to begin human studies than Moderna, Pfizer and other developers, the two are using a more established vaccine technology that they argue could deliver a more potent shot. The U.S. government has promised up to $2.1 billion in funding for the program, a sum second only to what's been pledged to Moderna.